



ASX Announcement

7 April 2020

## **Creso delivers shipment of anibidiol® to Virbac International, generating over AUD 200,000 in revenue**

### **Highlights**

- Creso Pharma has successfully completed all the exporting and importing procedures and delivered a significant shipment of anibidiol® Plus to Virbac International, on time, as planned, generating over AUD 200,000 in revenue for Creso Pharma.
- Virbac S.A. is among the leading global animal health companies and is marketing the anibidiol® product line in over 10 countries in Europe

**Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company')** is pleased to announce that it has completed the delivery of anibidiol® Plus to Virbac S.A. International at their headquarters in France, generating revenues for Creso Pharma of CHF 127'000 (or approximately AUD 215,000).

Virbac S.A. has been distributing the anibidiol® line throughout Europe since 2018 and has successfully expanded that distribution into over 10 countries to date. Creso Pharma continues to be encouraged by the positive feedback received from veterinary doctors and pet owners, which was reflected in the growth in animal health product sales of over 700% in 2019.

This delivery was achieved with the strong collaborative efforts of Creso's strategic partner, Domaco DNH Switzerland, and its logistic partners in Europe who were able to ensure no interruption to Creso's distribution chain, in spite of the challenges posed as a result of the global covid-19 pandemic.

### **anibidiol® Plus**

Creso Pharma developed the anibidiol® line for small, medium-sized and large pets to support the reduction of stress and help animals' nervous systems to function well. Pet owners report anibidiol® has also contributed to the management of pain and improved the vitality of their pets after one week of use in addition to normal feed.

Creso Pharma developed anibidiol® and has patented its granulated delivery system. anibidiol® is produced in Switzerland and is commercialised in collaboration with Virbac S.A. (EPA:VIRP) in over 10 countries in Europe.



**Dr. Miri Halperin Wernli, Co-Founder and CEO said:** “Our ability to deliver this order on time in a challenging environment is a testament to the professionalism and capabilities of our strategic partner, Domaco DMH and our supply and logistic partners in Europe. We are pleased to be able to ensure ongoing supply to a growing base of veterinary doctors and pet owners who are using our anibidiol® line of products throughout Europe”.

**Ends**

### **Authority and Contact Details**

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

For further information, please contact:

### **Investor Enquiries**

EverBlu Capital

E: [info@everblucapital.com](mailto:info@everblucapital.com)

P: +61 2 8249 0000

### **About Creso Pharma**

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary



innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: [www.cresopharma.com](http://www.cresopharma.com)

#### **About Virbac**

<https://corporate.virbac.com/home-en.html>

<https://www.virbac.ch/de/>

Virbac is an independent pharmaceutical laboratory dedicated to animal health, since its beginning. Currently the world's 7th largest animal health company with presence in more than 100 countries with more than 4,800 employees and sales subsidiaries in 33 countries. Virbac offers a comprehensive and practical range of products and services covering the majority of species and pathologies.

#### **About Domaco, Dr. med Aufdermaur AG**

Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms which is a way of preparing and compounding medicines in order to optimise their absorption.

#### **Forward Looking statements**

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation. The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.